Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 28, 2006; 12(44): 7081-7086
Published online Nov 28, 2006. doi: 10.3748/wjg.v12.i44.7081
Published online Nov 28, 2006. doi: 10.3748/wjg.v12.i44.7081
Table 1 Treatment response at the end of 24-wk follow-up after 24-wk therapy with IFN α2a 4.5 MIU tiw, 90 mcg/wk, 180 mcg/wk and 270 mcg/wk PEG IFN α2a (Adapted from W Cooksley et al[12])
| Response at the end ofthe 24-wk follow-up | 4,5 MU IFN(n = 51) | 90 μg PEG IFN α2a(n = 49) | 180 μg PEG IFN α2a(n = 46) | 270 μg PEG IFN α2a(n = 48) |
| НВV DNA < 500 000 cp/mL | 13 (25%) | 21 (43%) | 18 (39%) | 13 (27%) |
| Loss of HBeAg | 13 (25%) | 18 (37%) | 16 (35%) | 14 (29%) |
| HBeAg seroconversion | 13 (25%) | 18 (37%) | 15 (33%) | 13 (27%) |
| Normal ALT | 13 (25%) | 21 (43%) | 16 (35%) | 15 (31%) |
| Combined response1 | 6 (12%) | 13 (27%) | 13 (28%) | 9 (19%) |
- Citation: Krastev ZA. The “return” of hepatitis B. World J Gastroenterol 2006; 12(44): 7081-7086
- URL: https://www.wjgnet.com/1007-9327/full/v12/i44/7081.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i44.7081